The company has preannounced a suite of new aligner materials, software, and treatment solutions slated for 2027, with its Halo retention system available now for North American doctors.
Angelalign Technology Inc has unveiled six clinical innovations designed for North American doctors. While most of the features and materials are preannounced for 2027, the company’s Halo retention system is available now.
New Clinical Innovations for 2027
The 2027 lineup includes the SuperElastic (MC-SE) aligner material, which offers a large elastic range, strength, and toughness for tooth movement. The material will be available pending appropriate registrations.
The company also introduced the Adapt-MA system (pictured), a mandibular advancement tool for growth guidance in young patients with hyperdivergent to hypodivergent growth patterns.
Additionally, the release includes a DeepBite Solution that quadruples the treatable indication of tooth overjet compared to current products, along with new Pressure Points and trimlines designed to improve force expression and aligner contact.
Software and Retention Solutions
To support treatment planning, Angelalign announced iPlan software, which uses intelligent algorithms to help clinicians quickly revise plans and staging.
Currently available to doctors is the Halo Retention system, an expanded functional retention solution designed to prevent the relapse of conditions including deepbite, Class III, and tongue thrusting.
Industry Perspectives
“Angel was founded by orthodontic professors and is committed to being the standard bearer of innovation in the specialty,” says Bindu Saran, VP of product strategy, in a release. “We want to help premium orthodontists stand out in their treatment capabilities. Our innovations are effective because we listen closely to what specialists ask for and satisfy their needs.”
David Sarver, DMD, MS, an orthodontist and educator, noted the demand for high-quality outcomes in the specialty.
“In over four decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average,” says Sarver, in a release.
Photo: Angelalign Technology